Literature DB >> 25785168

Increased production of soluble vascular endothelial growth factors receptor-1 in CHO-cell line by using new combination of chitosan-protein lipid nanoparticles.

Poopak Farnia1, Jalaledin Ghanavi1, Afshin Bahrami1, Mojgan Bandehpour2, Bahram Kazemi2, Ali Akbar Velayati3.   

Abstract

The soluble vascular endothelial growth factor receptor-1 (VEGFR1) or sFLT-1 has important role in antiangiogenesis. In this study, the increase expression and production of sFLT-1 fragment by newly designed ChPL-NPs nanoparticles (chitosan-protein lipid) using Chinese hamster ovary cell line (CHO) was evaluated. The assessment and purification of sFLT-1 were carried out by western blotting and fast protein liquid chromatography (FPLC). Thereafter, the angiostatic effect of gene transfer of sFLT-1 in Human umbilical vein endothelial cell line (HUVEC) was evaluated. Our results showed a significance rate of transfection with ChPL-NPs (80-85%) in comparison to standard lipofectamine(2000) (65-70%) (P < 0.05). The anti-angiogenic action of sFLT-1 was observed by in-vitro culture of recombinant protein (sFLT-1; 50 ng/ml) with HUVEC cell lines (5 × 10(6)). The ChPL-NPs nanoparticles can consider a potential carrier system for large scale production of sFLT-1, which ultimately may be use as therapeutic agent in targeting solid tumor tissues.

Entities:  

Keywords:  ChPL-NPs; VEGFR1; antiangiogenesis; nanoparticles; sFLT-1

Year:  2015        PMID: 25785168      PMCID: PMC4358623     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  29 in total

1.  Cloning and expression of soluble vascular endothelial growth factors receptor-1 (sFlt-1) fragments in CHO-K1.

Authors:  Poopak Farnia; Mojgan Bandehpour; Jalaledin Ghanavi; Bahram Kazemi
Journal:  Int J Clin Exp Med       Date:  2013-09-25

Review 2.  Vascular endothelial growth factor.

Authors:  N Ferrara
Journal:  Eur J Cancer       Date:  1996-12       Impact factor: 9.162

Review 3.  Mechanisms of angiogenesis.

Authors:  W Risau
Journal:  Nature       Date:  1997-04-17       Impact factor: 49.962

4.  Chitosan-pDNA nanoparticle characteristics determine the transfection efficacy of gene delivery to human mesenchymal stem cells.

Authors:  Elham Malakooty Poor; Mohamadreza Baghaban Eslaminejad; Nematollah Gheibi; Fatemeh Bagheri; Fatemeh Atyabi
Journal:  Artif Cells Nanomed Biotechnol       Date:  2013-09-03       Impact factor: 5.678

5.  Anionic liposomal delivery system for DNA transfection.

Authors:  Siddhesh D Patil; David G Rhodes; Diane J Burgess
Journal:  AAPS J       Date:  2004-10-15       Impact factor: 4.009

6.  Up-regulation of VEGF expression and related neo-angiogenesis in childhood high-grade gliomas: implications for anti-angiogenic anti-neoplastic therapy.

Authors:  Bela Bodey; Stuart E Siegel; Hans E Kaiser
Journal:  In Vivo       Date:  2006 Jul-Aug       Impact factor: 2.155

7.  Oxygen radical-mediated pulmonary toxicity induced by some cationic liposomes.

Authors:  S Dokka; D Toledo; X Shi; V Castranova; Y Rojanasakul
Journal:  Pharm Res       Date:  2000-05       Impact factor: 4.200

8.  Delivery of soluble VEGF receptor 1 (sFlt1) by gene electrotransfer as a new antiangiogenic cancer therapy.

Authors:  Julien Verrax; Florence Defresne; Florence Lair; Gaëlle Vandermeulen; Géraldine Rath; Chantal Dessy; Véronique Préat; Olivier Feron
Journal:  Mol Pharm       Date:  2011-05-13       Impact factor: 4.939

9.  Serum-free large-scale transient transfection of CHO cells.

Authors:  Madiha Derouazi; Philippe Girard; Frédéric Van Tilborgh; Keyvan Iglesias; Natalie Muller; Martin Bertschinger; Florian M Wurm
Journal:  Biotechnol Bioeng       Date:  2004-08-20       Impact factor: 4.530

10.  Soluble Fms-like tyrosine kinase-1 expression inhibits the growth of multiple myeloma in nude mice.

Authors:  Junru Liu; Juan Li; Chang Su; Beihui Huang; Shaokai Luo
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2007-07       Impact factor: 3.848

View more
  1 in total

1.  Delivery of sFIT-1 engineered MSCs in combination with a continuous low-dose doxorubicin treatment prevents growth of liver cancer.

Authors:  Jian Niu; Yue Wang; Ji Wang; Liu Bin; Xin Hu
Journal:  Aging (Albany NY)       Date:  2016-12-28       Impact factor: 5.682

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.